BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 1999

View Archived Issues

Droloxifene plus PGE2 effectively restores and maintains bone mass

Read More

Fomepizole, an effective antidote to ethylene glycol poisoning

Read More

BioChem Pharma licenses antiviral technology from OSI Pharmaceuticals

Read More

Megabios and GeneMedicine complete merger; combined company to be named Valentis

Read More

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

Read More

Pharmacyclics updates Antrin photoangioplasty trial interim results

Read More

Bioniche technology offers synergistic benefits in cancer therapy

Read More

Halving dose of Preveon does not reduce its efficacy in HIV

Read More

More positive clinical data on new antibiotic linezolid presented at ECCMID

Read More

Algos: Q4 and year-end 1998 highlights

Read More

Enrollment completed for trial of InKine purgative tablets

Read More

Function of anandamide discovered

Read More

Iomed to develop drugs to treat local inflammation, ocular disease and pain control

Read More

Structurally distinct 5-HT ligands for depression, anxiety discovered at SB

Read More

Patent issued to Pfizer for NPY antagonist series

Read More

Novel series from Egis with muscle relaxant, neuroprotective and anticonvulsant activity

Read More

Novel quinolone antibacterial agents discovered at Korean research institute

Read More

New Sustiva clinical data reported at European congress

Read More

New candidate for treatment of atopic dermatitis synthesized at Nissan Chemical

Read More

U.S. patent issues to Vivus for second-generation ED therapeutic

Read More

British Biotech completes strategic review, defines new priorities

Read More

TEI-9874, an allergen-specific IgE production inhibitor for treatment of allergic asthma

Read More

FDA approves Duramed's Cenestin for treatment of menopause symptoms

Read More

CPMP opinion favors approval of Glaxo Wellcome's Ziagen

Read More

FDA grants world's first approval for a single-isomer bronchodilator

Read More

Biora creates new subsidiary to develop products for use outside the oral cavity

Read More

More ACS news: SmithKline Beecham continues to research CXCR2 antagonists

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing